Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

blueprint medicines - BPMC

BPMC

Close Chg Chg %
88.93 1.21 1.36%

Closed Market

90.14

+1.21 (1.36%)

Volume: 1.27M

Last Updated:

Dec 20, 2024, 4:00 PM EDT

Trade Now

Company Overview: blueprint medicines - BPMC

BPMC Key Data

Open

$88.12

 Day Range

87.99 - 90.99

52 Week Range

72.25 - 121.90

 Market Cap

$5.65B

Shares Outstanding

63.53M

 Public Float

61.55M

Beta

0.58

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.06

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

673.06K

  

BPMC Performance

1 Week
 
 -3.27%
 
1 Month
 
 -4.26%
 
3 Months
 
 -1.68%
 
1 Year
 
 1.47%
 
5 Years
 
 13.41%
 

BPMC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 21
Full Ratings ➔

About blueprint medicines - BPMC

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

BPMC At a Glance

Blueprint Medicines Corp.
45 Sidney Street
Cambridge, Massachusetts 02139
Phone 1-617-374-7580 Revenue 249.38M
Industry Biotechnology Net Income -506,984,000.00
Sector Health Technology 2023 Sales Growth 22.224%
Fiscal Year-end 12 / 2024 Employees 655
View SEC Filings

BPMC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 22.399
Price to Book Ratio 43.184
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -11.903
Enterprise Value to Sales 22.654
Total Debt to Enterprise Value 0.137

BPMC Efficiency

Revenue/Employee 380,732.824
Income Per Employee -774,021.374
Receivables Turnover 5.776
Total Asset Turnover 0.208

BPMC Liquidity

Current Ratio 3.761
Quick Ratio 3.663
Cash Ratio 3.306

BPMC Profitability

Gross Margin 90.191
Operating Margin -194.994
Pretax Margin -202.91
Net Margin -203.298
Return on Assets -42.264
Return on Equity -157.135
Return on Total Capital -56.037
Return on Invested Capital -51.573

BPMC Capital Structure

Total Debt to Total Equity 592.702
Total Debt to Total Capital 85.564
Total Debt to Total Assets 73.779
Long-Term Debt to Equity 530.372
Long-Term Debt to Total Capital 76.566
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Blueprint Medicines - BPMC

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
793.74M 180.08M 204.04M 249.38M
Sales Growth
+1,093.37% -77.31% +13.30% +22.22%
Cost of Goods Sold (COGS) incl D&A
12.78M 38.52M 46.86M 24.46M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
12.35M 12.79M 20.10M 11.66M
Depreciation
12.35M 12.79M 20.10M 11.66M
Amortization of Intangibles
- - - -
-
COGS Growth
- +201.53% +21.65% -47.80%
Gross Income
780.96M 141.56M 157.18M 224.92M
Gross Income Growth
- -81.87% +11.03% +43.10%
Gross Profit Margin
+98.39% +78.61% +77.03% +90.19%
2020 2021 2022 2023 5-year trend
SG&A Expense
472.25M 783.54M 694.69M 711.20M
Research & Development
320.30M 594.55M 465.68M 416.06M
Other SG&A
151.95M 188.99M 229.01M 295.14M
SGA Growth
+13.09% +65.92% -11.34% +2.38%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
308.71M (641.98M) (537.52M) (486.28M)
Non Operating Income/Expense
6.23M 897.00K 2.00M 31.87M
Non-Operating Interest Income
- 6.60M 2.39M 32.81M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 16.77M 51.60M
-
Interest Expense Growth
- - - +207.78%
-
Gross Interest Expense
- - 16.77M 51.60M
-
Interest Capitalized
- - - -
-
Pretax Income
314.94M (641.08M) (552.28M) (506.02M)
Pretax Income Growth
+190.58% -303.56% +13.85% +8.38%
Pretax Margin
+39.68% -356.00% -270.68% -202.91%
Income Tax
1.06M 3.00M 5.24M 968.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
313.88M (644.09M) (557.52M) (506.98M)
Minority Interest Expense
- - - -
-
Net Income
313.88M (644.09M) (557.52M) (506.98M)
Net Income Growth
+190.28% -305.20% +13.44% +9.06%
Net Margin Growth
+39.54% -357.67% -273.24% -203.30%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
313.88M (644.09M) (557.52M) (506.98M)
Preferred Dividends
- - - -
-
Net Income Available to Common
313.88M (644.09M) (557.52M) (506.98M)
EPS (Basic)
5.7557 -11.0066 -9.3477 -8.3719
EPS (Basic) Growth
+179.18% -291.23% +15.07% +10.44%
Basic Shares Outstanding
54.53M 58.52M 59.64M 60.56M
EPS (Diluted)
5.5883 -11.0066 -9.3477 -8.3719
EPS (Diluted) Growth
+176.87% -296.96% +15.07% +10.44%
Diluted Shares Outstanding
56.17M 58.52M 59.64M 60.56M
EBITDA
321.06M (629.20M) (517.42M) (474.61M)
EBITDA Growth
+191.45% -295.98% +17.77% +8.27%
EBITDA Margin
+40.45% -349.40% -253.59% -190.32%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 125.316
Number of Ratings 21 Current Quarters Estimate -0.697
FY Report Date 12 / 2024 Current Year's Estimate -0.978
Last Quarter’s Earnings -0.89 Median PE on CY Estimate N/A
Year Ago Earnings -8.37 Next Fiscal Year Estimate -0.922
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 19 11 18 19
Mean Estimate -0.70 -0.55 -0.98 -0.92
High Estimates -0.51 -0.30 -0.78 2.92
Low Estimate -0.96 -0.78 -1.26 -2.84
Coefficient of Variance -16.35 -25.68 -12.24 -158.72

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 13 13
OVERWEIGHT 1 1 1
HOLD 5 5 4
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Blueprint Medicines - BPMC

Date Name Shares Transaction Value
Aug 20, 2024 Michael Landsittel CHIEF FINANCIAL OFFICER 67,208 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $95.23 per share 6,400,217.84
Jul 3, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 12,667 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 3, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 43,763 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $111.15 per share 4,864,257.45
Jul 3, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 44,096 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $54.13 per share 2,386,916.48
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 43,763 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102.44 per share 4,483,081.72
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 44,063 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.05 per share 4,540,692.15
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 117,797 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $54.13 per share 6,376,351.61
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 97,478 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.98 per share 10,233,240.44
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 57,125 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.14 per share 5,948,997.50
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 13,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 26, 2024 Bumpus Durso CHIEF PEOPLE OFFICER 116,230 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $105.82 per share 12,299,458.60
Jun 7, 2024 Becker Hewes CHIEF MEDICAL OFFICER 29,514 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.91 per share 3,096,313.74
Jun 6, 2024 Percy H. Carter CHIEF SCIENTIFIC OFFICER 45,895 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $106.43 per share 4,884,604.85
Jun 5, 2024 Becker Hewes CHIEF MEDICAL OFFICER 67,297 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $107.86 per share 7,258,654.42
Jun 5, 2024 Becker Hewes CHIEF MEDICAL OFFICER 64,106 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $106.5 per share 6,827,289.00
Jun 5, 2024 Becker Hewes CHIEF MEDICAL OFFICER 70,968 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $43.15 per share 3,062,269.20
Jun 5, 2024 Becker Hewes CHIEF MEDICAL OFFICER 65,239 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $61.31 per share 3,999,803.09

Blueprint Medicines in the News